The effect of exercise on vascular health in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
Am J Physiol Renal Physiol. 2023 Sep 21. doi: 10.1152/ajprenal.00152.2023. Online ahead of print.ABSTRACTPatients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. This increased risk cannot be fully explained by traditional risk factors such as hypertension. Endothelial dysfunction and arterial stiffness have been suggested as factors which explain some of the increased risk, and are independently associated with important cardiovascular outcomes in CKD patients. Studies in other disease populations have shown positive effects of exercise on vascular dysfunction. The aim of this review was...
Source: American Journal of Physiology. Renal Physiology - September 21, 2023 Category: Physiology Authors: Mark D Davies Felicity Hughes Aamer Sandoo Abdulfattah Alejmi Jamie Hugo Macdonald Source Type: research

Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00
CONCLUSIONS: Our results show a differential benefit of low-dose CM therapy across different TNBC subtypes. Low-dose CM therapy could be considered as a potential immunomodulatory strategy for TNBC tumors with IM subtype in the early-disease setting.PMID:37733800 | DOI:10.1158/1078-0432.CCR-23-1267
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Andrea Joaquin Garcia Mattia Rediti David Venet Samira Majjaj Roswitha Kammler Elisabetta Munzone Lorenzo Gianni Beat Th ürlimann Istv án Láng Marco Colleoni Sherene Loi Giuseppe Viale Meredith M Regan Laurence Buisseret Fran çoise Rothé Christos Sot Source Type: research

Near-infrared spectral tomography for predicting residual cancer burden during early stage neoadjuvant chemotherapy for breast cancer
CONCLUSION: NIRST holds promise as a potential clinical tool that can be seamlessly integrated into existing clinical workflow within the infusion suite. By providing early assessment of RCB, NIRST has potential to improve breast cancer patient management strategies.PMID:37733788 | DOI:10.1158/1078-0432.CCR-23-1593
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Xu Cao Kristen E Muller Mary D Chamberlin Jiang Gui Peter A Kaufman Gary N Schwartz Roberta M DiFlorio-Alexander Brian W Pogue Keith D Paulsen Shudong Jiang Source Type: research

Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis
CONCLUSION: Oncologists may have increased flexibility regarding the frequency of administration of BTT along with their choice of agent. Our study showed no significant difference in the prevention of overall SRE or development of BTT-associated harms between the BTT regimens evaluated.PMID:37735019 | DOI:10.1016/j.clbc.2023.08.008
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Athira Jayan Akshara Singareeka Raghavendra Roland Bassett Carlos H Barcenas Source Type: research

Prepectoral Direct-To-Implant One-Stage Reconstruction With ADMs: Safety and Outcome in "Thin Patients"
CONCLUSIONS: Prepectoral reconstruction with ADM in thin patients may be considered as safe as in standard BMI patients. Rippling may be more frequent, but, whenever needed, easy to correct with a few sessions of lipo-grafts.LEVEL OF EVIDENCE: III.PMID:37735018 | DOI:10.1016/j.clbc.2023.08.007
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Anna Scarabosio Filippo Contessi Negrini Gaetano Pisano Yvonne Beorchia Luigi Castriotta Francesco De Francesco Michele Riccio Pier Camillo Parodi Nicola Zingaretti Source Type: research

Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer
CONCLUSION: This study has shown significance in reducing LD measurements on ultrasound as a predictor of PCR and RCB class. This adds weight to the current practice of using ultrasound at the start, mid and end of chemotherapy cycles to monitor NACT responses.PMID:37734976 | DOI:10.1016/j.crad.2023.07.010
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: H F Lim A Sharma C Gallagher P Hall Source Type: research

Toxicological profiling of a de novo synthesized benzimidazole derivative with potent and selective proapoptotic potentials against breast cancer
This study aimed to investigate the toxicological profile of 1-(6-(1H-benzo[d]imidazole-2-yl)-2-methylpyridin-3-yl) ethanone (BMPE), both in vitro and in vivo. The proapoptotic/necrotic and cell cycle arrest potentials of BMPE were assessed in MCF-7 cell line. The in vivo toxicology was assessed in female Balb/c mice by repeated dosing of 5, 25, and 50 mg/kg for 21 consecutive days, then different biochemical, inflammatory, and oxidative markers were assessed in sera/tissue homogenates of treated animals. The new derivative showed a potent selective cytotoxicity against malignant cell lines with IC50 value 0.2 μM/mL, whil...
Source: Food and Chemical Toxicology - September 21, 2023 Category: Food Science Authors: Ebtehal K Farrag Wessam M Aziz Sylvia E Shaker Heba Shawky Dalia B Fayed Source Type: research

Evaluation of intraoperative breast radiotherapy on local recurrence: a Brazilian cohort
CONCLUSIONS: The samples consisted of 78 patients, among which a total of 14 (17.9%) recurrences were observed. The median time of recurrence was 49 months after the IOERT was performed. Of the 78 patients analyzed, 13 (16.7%) died, 5 (6.4%) of which were due to breast cancer. The global survival rate in 5 years was 94.9% and 90.4% in 10 years. The local recurrence rate in 5 years was 89.7% and 86.4% in 10 years. Our findings revealed a higher local recurrence rate than the literature data. However, our results also showed that patients classified as low-risk had an overall survival of 5 and 10 years similar to other studi...
Source: International Journal of Radiation Biology - September 21, 2023 Category: Radiology Authors: Cintia Melo Sousa Izabella Nobre Queiroz Ana Paula Drummond-Lage Source Type: research

3D phantom for image quality assessment of mammography systems
Phys Med Biol. 2023 Sep 21. doi: 10.1088/1361-6560/acfc10. Online ahead of print.ABSTRACTOBJECTIVE: To present an innovative approach for the design of a 3D mammographic phantom for medical equipment quality assessment, estimation of the glandular tissue percentage in the patient's breast, and emulation of microcalcification ($\mu$C) breast lesions.APPROACH: Contrast-to noise ratio (CNR) measurements, as well as spatial resolution and intensity-to-glandularity calibrations under mammography conditions were performed to assess the effectiveness of the phantom. CNR measurements were applied to different groups of calcium hyd...
Source: Physics in Medicine and Biology - September 21, 2023 Category: Physics Authors: Jes ús David Bermúdez Sánchez Gerardo Alfonso Roque Juan Sebasti án Calderón García Paula Andrea Pardo Ramos Manuel Fernando S ánchez Alarcón Victor Alfonso Ramos Correa Carlos Arturo Ávila Bernal Source Type: research

Oestrogen receptor-independent actions of oestrogen in cancer
Mol Biol Rep. 2023 Sep 20. doi: 10.1007/s11033-023-08793-8. Online ahead of print.ABSTRACTOestrogen, the primary female sex hormone, plays a significant role in tumourigenesis. The major pathway for oestrogen is via binding to its receptor [oestrogen receptor (ERα or β)], followed by nuclear translocation and transcriptional regulation of target genes. Almost 70% of breast tumours are ER + , and endocrine therapies with selective ER modulators (tamoxifen) have been successfully applied. As many as 25% of tamoxifen-treated patients experience disease relapse within 5 years upon completion of chemotherapy. In such cases, t...
Source: Molecular Biology Reports - September 21, 2023 Category: Molecular Biology Authors: Prarthana Gopinath Revathi Paramasivam Oviya Gopal Gopisetty Source Type: research

Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00
CONCLUSIONS: Our results show a differential benefit of low-dose CM therapy across different TNBC subtypes. Low-dose CM therapy could be considered as a potential immunomodulatory strategy for TNBC tumors with IM subtype in the early-disease setting.PMID:37733800 | DOI:10.1158/1078-0432.CCR-23-1267
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Andrea Joaquin Garcia Mattia Rediti David Venet Samira Majjaj Roswitha Kammler Elisabetta Munzone Lorenzo Gianni Beat Th ürlimann Istv án Láng Marco Colleoni Sherene Loi Giuseppe Viale Meredith M Regan Laurence Buisseret Fran çoise Rothé Christos Sot Source Type: research

AZI2 mediates TBK1 activation at unresolved selective autophagy cargo receptor complexes with implications for CD8 T-cell infiltration in breast cancer
Autophagy. 2023 Sep 21. doi: 10.1080/15548627.2023.2259775. Online ahead of print.ABSTRACTMost breast cancers do not respond to immune checkpoint inhibitors and there is an urgent need to identify novel sensitization strategies. Herein, we uncovered that activation of the TBK-IFN pathway that is mediated by the TBK1 adapter protein AZI2 is a potent strategy for this purpose. Our initial observations showed that RB1CC1 depletion leads to accumulation of AZI2, in puncta along with selective macroautophagy/autophagy cargo receptors, which are both required for TBK1 activation. Specifically, disrupting the selective autophagy ...
Source: Autophagy - September 21, 2023 Category: Cytology Authors: Syn Kok Yeo Michael Haas Kanakaraju Manupati Mingang Hao Fuchun Yang Song Chen Jun-Lin Guan Source Type: research

Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin
CONCLUSION: Baseline IL-6 is an important prognostic factor in patients with MBC treated with eribulin. Our results show that high IL-6 is associated with higher levels of MDSCs which suppress anti-tumor immunity, such as CD8+ cells. It appears that eribulin is not particularly effective in patients with high IL-6 due to a poor tumor immune microenvironment.PMID:37733188 | DOI:10.1007/s10549-023-07086-9
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Ayako Bun Masayuki Nagahashi Mamiko Kuroiwa Miki Komatsu Yasuo Miyoshi Source Type: research

Eribulin promotes proliferation of CD8 < sup > + < /sup > T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells
CONCLUSIONS: Eribulin promoted CD8+ T cell proliferation, repressed effector T cell differentiation, and harnessed T cell-mediated anti-tumor effects. These mechanisms may be one of the cues that eribulin can improve the immunological status of tumor-bearing hosts.PMID:37733186 | DOI:10.1007/s10549-023-07111-x
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Tadafumi Shimizu Takaaki Oba Masanori Oshi Ken-Ichi Ito Source Type: research

Chromatin accessibility landscape of human triple-negative breast cancer cell lines reveals variation by patient donor ancestry
Cancer Res Commun. 2023 Sep 21. doi: 10.1158/2767-9764.CRC-23-0236. Online ahead of print.ABSTRACTAfrican American (AA) women have an excessive risk of developing triple-negative breast cancer (TNBC). We employed ATAC-sequencing to characterize differences in chromatin accessibility between 9 commonly used TNBC cell lines derived from patients of European and African ancestry. Principal component and chromosome mapping analyses of accessibility peaks with the most variance revealed separation of chromatin profiles by patient group. Motif enrichment and footprinting analyses of disparate open chromatin regions revealed diff...
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Alexandra R Harris Gatikrushna Panigrahi Huaitian Liu Vishal N Koparde Maeve Bailey-Whyte Tiffany H Dorsey Clayton C Yates Stefan Ambs Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20